IPP Bureau
Pfizer Q1 2025 revenue drops 8% to $13.7 billion
By IPP Bureau - April 29, 2025
Delivers robust earnings performance, successfully navigating a dynamic environment
Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion
By IPP Bureau - April 28, 2025
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Biocon Biologics receives positive CHMP opinions for biosimilar Denosumab in Europe
By IPP Bureau - April 28, 2025
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA
By IPP Bureau - April 28, 2025
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Dr. Lal Path Labs posts Q4 FY25 consolidated PAT at Rs. 154.8 Cr
By IPP Bureau - April 28, 2025
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
Zydus Lifesciences to acquire 85.6 % stake in Amplitude Surgical
By IPP Bureau - April 26, 2025
The closing of the Block Acquisition is now expected to be completed by Q3 2025
FUJIFILM India to sell Spectra Logic’s tape storage products, software in India
By IPP Bureau - April 25, 2025
Distribution agreement enables FUJIFILM India to offer Spectra Logic advanced tape libraries and software solutions to enterprise customers and channel partners
We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer
By IPP Bureau - April 25, 2025
Bayer expects 2025 to be the most difficult year of its turnaround
Briefs: Ami Organics and Panacea Biotec
By IPP Bureau - April 25, 2025
Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan
Suven Pharmaceuticals get final approval to amalgamate Cohance Lifesciences
By IPP Bureau - April 25, 2025
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Syngene International posts Q4 FY25 consolidated profit at Rs. 183.3 Cr
By IPP Bureau - April 24, 2025
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Thyrocare Technologies Q4 FY25 consolidated PAT up at Rs. 21.70 Cr
By IPP Bureau - April 24, 2025
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
Akums and Tamil Nadu Agricultural University announce partnership for pharmaceutical innovation
By IPP Bureau - April 24, 2025
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
Pfizer advances vision for future of cancer care at ASCO 2025 Annual Meeting
By IPP Bureau - April 24, 2025
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Sun Pharma and Moebius Medical announce dual publications on MM-II’s phase 2b clinical trial results in Osteoarthritis and Cartilage
By IPP Bureau - April 24, 2025
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
